Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Palisade Bio Inc PALI
$1.90
▼ -3.32%
($-0.07)
⬇️ Below Yest. Low
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$1.94
Prev Close
$1.96
Day Range
$1.86 – $1.95
52W Range
$0.53 – $2.86
Market Cap
$328.93M
Beta
1.46
EPS (TTM)
$-1.17
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-12-20 |
| Shares Out. | 173,580,000 |
| Website | palisadebio.com/ ↗ |
| Phone | 13026974590 |
| Employees | 14 |
| Net Income | -$9.6M |
| Total Assets | $133.3M |
| Total Liabilities | $6.0M |
| Equity | $127.4M |
About Palisade Bio Inc
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Palisade Bio Inc is a publicly traded company under the ticker symbol PALI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)